Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,531.48 29.83 0.18%
S&P 500 1,880.57 5.18 0.28%
NASDAQ 4,157.86 30.90 0.75%
Ticker Volume Price Price Delta
STOXX 50 3,182.84 6.87 0.22%
FTSE 100 6,690.78 16.04 0.24%
DAX 9,529.98 -14.21 -0.15%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Advanced Cell Technology Achieves Clinical Milestone



  Advanced Cell Technology Achieves Clinical Milestone

    Company is Halfway through Groundbreaking Clinical Trials; Evidence of
         Engraftment and Function Observed; No Safety Issues Reported

Business Wire

MARLBOROUGH, Mass. -- January 8, 2013

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader
in the field of regenerative medicine, announced today that investigators for
the Company’s Phase I/II clinical trials for Stargardt’s macular dystrophy
(SMD) and dry age-related macular degeneration (dry AMD) have observed
evidence of engraftment of the transplanted human embryonic stem cell
(hESC)-derived retinal pigment epithelial (RPE) cells and visual acuity gain
in patients treated over the 18 months since the trials were first initiated.
The Company believes this observation of engraftment and persistence is
clinically important because engraftment of cells in the proper area, and
recapitulation of normal RPE cell layer structure is important to the ultimate
efficacy of the RPE cells in the treatments. Additionally, investigators have
not observed any issues of safety relating to the transplanted human embryonic
stem cell (hESC)-derived RPE cells in any of the 18 patients treated. The
company believes this warrants early (though cautious) optimism as the company
looks forward to initiating the second half of the three trials.

“Now that we are at the halfway point in all three of our ongoing trials, we
have had the opportunity to stop and assess not only the data relating to
safety, but also to the activity of the transplanted RPE cells,” said Gary
Rabin, chairman and CEO. “In our first report of hESC-derived cells
transplanted into patients, published in the Lancet, we reported no adverse
safety signals and that both patients that had been treated by that point
showed some signs of visual improvements. For both of those patients, those
gains in visual acuity have persisted for nearly 18 months now. In addition,
we have observed persisting engraftment of the transplanted RPE cells in our
more recent SMD and dry AMD patients. This is the first time we have shown
this in dry AMD patients, which we find particularly encouraging, given that
dry AMD represents one of the largest unmet medical needs in the world.”

“We are optimistic about the prospects of our RPE cells ultimately impacting
positively on various forms of macular degeneration,” said Robert Lanza, M.D.,
ACT’s chief scientific officer. “As we have added additional clinical trial
sites, the pace of patient treatments has picked up. At the same time, we are
extending our observations to a greater number of patients, as well as
collecting data over extended periods of time after the surgery.”

Mr. Rabin will be providing an overview of the company’s progress, including
providing some representative examples of anatomical data of RPE engraftment
in the trials, in his presentation on Tuesday, Jan. 8 at Biotech Showcase 2013
in San Francisco. Pictures of the engraftment will be included in Mr. Rabin’s
presentation, which will be posted to the Presentations section of the ACT
site, and a link to a webcast of the presentation will be available on the
Events section.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement